Sotorasib is a potent and selective inhibitor of KRAS G12C mutant protein, which is involved in the development of various types of cancer. The impurities in Sotorasib can affect its purity, potency, and safety, thereby influencing the efficacy and safety of the drug. The identification, characterization, and control of Sotorasib impurities are crucial for ensuring the quality and safety of the drug product. Various analytical methods, such as HPLC, LC-MS, and NMR, are used to detect and quantify the impurities in Sotorasib.
